Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / EYPT - EyePoint Is Betting The Bank On EYP-1901

EYPT - EyePoint Is Betting The Bank On EYP-1901

EyePoint Pharmaceuticals Inc.

2024-02-21 08:36:08 ET

Summary

  • EyePoint's EYP-1901 shows promising results in a Phase 2 trial for multiple eye conditions, potentially becoming the standard of care.
  • The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business.
  • EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing.

EyePoint ( EYPT ) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901....

For further details see:

EyePoint Is Betting The Bank On EYP-1901
Stock Information
Company Name: EyePoint Pharmaceuticals Inc.
Stock Symbol: EYPT
Market: NASDAQ
Website: eyepointpharma.com
Menu
EYPT EYPT Quote EYPT Short EYPT News EYPT Articles EYPT Message Board
Get EYPT Alerts

News, Short Squeeze, Breakout and More Instantly...